Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psilocybin + trazodone
- Development stage
- Unknown
- Lead developer
- Hôpital Sainte-Anne
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Psilocybin + trazodone is an experimental combination therapy being investigated by Centre Hospitalier St Anne for the treatment of treatment-resistant depression (TRD). Psilocybin is a prodrug of psilocin, a potent agonist at the serotonin 5-HT2A receptor, known for its rapid antidepressant effects and neuroplasticity-inducing properties. Trazodone is an antidepressant that acts as a 5-HT2A receptor antagonist. This combination is being evaluated in the Phase 2 PSILOTRAZ trial to determine if the therapeutic antidepressant benefits of psilocybin can be decoupled from its acute subjective psychedelic effects by blocking the 5-HT2A receptor during administration. The psilocybin component used in this specific study is PEX010, a botanical extract developed by Filament Health.
- Brand names
- PEX010PEX-010PEX 010
- Other names
- Psilocybin and Trazodone combination
02
Targets
HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on psilocybin + trazodone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psilocybin + trazodone.